Many cancer patients may need a sequential one-two punch of immunotherapies
LA JOLLA, CA--New research led by scientists at La Jolla Institute for Immunology (LJI) and the University of Liverpool may explain why many cancer patients do not respond to anti-PD-1 cancer immunotherapies--also called checkpoint inhibitors.
The team reports that these patients may have tumors with high numbers of T follicular regulatory (Tfr) cells.
In a healthy person, Tfr cells do the important job of stopping haywire T cells and autoantibodies from attacking the body's own tissues. But in a cancer patient, Tfr cells dramatically dial back the body's ability to kill cancer cells.
Anti-PD-1 cancer immunotherapies boost the body's cancer-fighting T cells, but ...











